Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
26 juin 2024 19h05 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
26 juin 2024 16h05 HE
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
AI Brain Health Leader Omniscient Closes Series C Funding Round
11 juin 2024 11h00 HE
|
Omniscient Neurotechnology
Omniscient secures Series C funding to expand Quicktome® platform, advancing connectomics for improved brain health diagnostics and treatments.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
11 juin 2024 08h00 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
07 juin 2024 15h32 HE
|
Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
06 juin 2024 18h14 HE
|
Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
28 mai 2024 08h00 HE
|
Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
16 mai 2024 14h00 HE
|
Tevogen Bio Inc
Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space.
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
15 mai 2024 08h30 HE
|
PaxMedica, Inc.
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for...
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
10 mai 2024 17h40 HE
|
Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.